Review

The Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt?

Katherine E. Kunigelis and Michael W. Graner *

Department of Neurosurgery, Anschutz Medical Campus, University of Colorado Denver, Aurora, CO 80045, USA; E-Mail: katherine.kunigelis@ucdenver.edu

* Author to whom correspondence should be addressed; E-Mail: michael.graner@ucdenver.edu; Tel.: +1-303-724-4133; Fax: +1-303-724-6012.

Academic Editor: Darrell J. Irvine

Received: 14 October 2015 / Accepted: 5 December 2015 / Published: 17 December 2015

Abstract: Exosomes are virus-sized nanoparticles (30–130 nm) formed intracellularly as intravesicular bodies/intralumenal vesicles within maturing endosomes (“multivesicular bodies”, MVBs). If MVBs fuse with the cell’s plasma membrane, the interior vesicles may be released extracellularly, and are termed “exosomes”. The protein cargo of exosomes consists of cytosolic, membrane, and extracellular proteins, along with membrane-derived lipids, and an extraordinary variety of nucleic acids. As such, exosomes reflect the status and identity of the parent cell, and are considered as tiny cellular surrogates. Because of this closely entwined relationship between exosome content and the source/status of the parental cell, conceivably exosomes could be used as vaccines against various pathologies, as they contain antigens associated with a given disease, e.g., cancer. Tumor-derived exosomes (TEX) have been shown to be potent anticancer vaccines in animal models, driving antigen-specific T and B cell responses, but much recent literature concerning TEX strongly places the vesicles as powerfully immunosuppressive. This dichotomy suggests that the context in which the immune system encounters TEX is critical in determining immune stimulation versus immunosuppression. Here, we review literature on both sides of this immune coin, and suggest that it may be time to revisit the concept of TEX as anticancer vaccines in clinical settings.

Keywords: exosomes/microvesicles/extracellular vesicles; tumor-derived exosomes (TEX); dendritic cell-derived exosomes (DEX); cancer vaccine; immune suppression; antigen presenting cells; T cells; B cells; natural killer cells
1. Introduction

Extracellular vesicles such as exosomes and microvesicles are now reasonably considered to be particularly important players in both the normal and pathological functions of cells, organs, and organisms [1]. Their roles in many biologic processes [2] are increasingly recognized, if not understood, including in immune function/dysfunction in relation to cancer [3–5]. Here, we will review some of the immune properties of exosomes/microvesicles in the context of cancer biology, where the vesicles may play dual roles in terms of immune stimulators (potentially having vaccine characteristics) and immune suppressors. We will argue that this dichotomy is likely due to the context in which the immune system sees the vesicles, and those circumstances may be deciding factors in the direction taken by the immune response.

1.1. Concerning Nomenclature

The terminology of secreted or extracellularly released nanovesicles is diverse, confusing, and perhaps, at times, whimsical. The literature on the topic yields dozens of different names for what are (now, tentatively) collectively called extracellular vesicles (EVs) [6]. Generally, EVs from typical eukaryotic cells are regarded as belonging to one of three categories [2]: “apoptotic bodies/blebs” coming from vacuolization or membranous vesiculation of cells dying from apoptotic processes (diameters ~1 μm to 5 μm); “microvesicles”, “microparticles” or “ectosomes” (and other terms) where vesicles are directly released or “shed” from the plasma membrane (diameters ~130 nm to 1 μm); and “exosomes”, referring specifically to the release of endosomally derived intralumenal vesicles of multivesicular bodies, as explained below (diameters ~30 to 130 nm) [7]. From an experimental viewpoint, different separation techniques tend to produce somewhat distinct vesicle types, but there is undoubtedly overlap, for instance at the high-end size of the “exosomes” and the low-end size of the “microvesicles”, in terms of protein markers and activities [8,9]. However, most of the literature we will review here regards vesicles with sizes and characteristics consistent with what are generally termed “exosomes”, and we will employ that term throughout the rest of this article.

2. Exosomes

As stated, exosomes are nanoparticles (30–130 nm) formed by inward budding of endosomal membranes to form multivesicular bodies (MVBs). MVBs canonically converge to lysosomal degradation; a multitude of intracellular and extracellular conditions may instead drive MVBs to fuse with the cell plasma membrane to release their intralumenal vesicles as exosomes [10]. This is illustrated in Figure 1. One of their main functions is in intercellular communication, and as such, their contents represent their native environment, including proteins, lipids, and nucleic acids. They stand as surrogates of the status and identity of their cells of origin [11]. For this reason, exosomes procured from bodily fluids are proposed to be potentially extraordinary biomarkers of disease [12,13], and could be the chief diagnostic components of “liquid biopsy” [14–16].
Figure 1. Exosome formation in a generic cell (nothing is drawn to scale). Exosomes are virus-sized (30–130 nm diameter) vesicles formed within the endosomal system that are released extracellularly. (A) shows an endocytic event (which could be clathrin- or caveolin-mediated, or independent; or phagocytic, or (macro) pinocytic). An early endosome is formed in (B); note the orientation of the membranes (blue or red outlines) and the nature of the former surface proteins (previously with extracellular domains that are now intralumenal within the endosome). In (C), membrane invaginations occur (largely through the efforts of the unshown ESCRT machinery) which push the transmembrane proteins into the endosomal lumen, and sequester cytosolic molecules (proteins: brown dots; nucleic acids: purple squiggle lines) inside intralumenal vesicles, as seen in (D). (D) represents a “multivesicular body” (MVB), a late endosomal intracellular vesicle with smaller vesicles within it. In (E), the MVB fuses with the plasma membrane to release the intralumenal vesicles outside the cell; these are now termed “exosomes”. Note that the membrane/membrane protein topography (as well as the cytosolic components) now recapitulates the original exterior and interior compartmentalization.

Exosomes are secreted or released by essentially all cell types, certainly most immune and non-immune cells including macrophage, dendritic cells (DCs), B cells, T cells such as CD8+ cytotoxic T-lymphocytes (CTLs) and CD4+ T helper (Th) cells, platelets, mastocytes, fibroblasts, epithelial cells, as well as tumor cells. Exosomes participate in important biological functions, acting as a mode of communication between cells that does not require cell-cell contact, and can thus occur over significant distances [17]. This intercellular communication can be conferred by mediators that are expressed or displayed on the exosome surfaces, thus mimicking cell-cell interaction to some extent. Exosomes produced by both immune and non-immune cells have the ability to regulate immune responses [18], thus demonstrating an impact of exosomes in webs of intercellular, and inter-system, communications [19,20].
2.1. Tumor-Derived Exosomes (TEX)

Although the best-studied microvesicles in the cancer immunotherapy field are (arguably) exosomes, tumor-derived exosomes (TEX) are still associated with seemingly conflicting roles of immune stimulation as well as suppression of both tumor-specific and nonspecific immune responses [21,22]. As the induction of an active immune response to control or eliminate tumors remains an unfulfilled challenge, TEX have been proposed for a role in cancer immunotherapy through harnessing a source of cancer cell antigens for antitumor immune responses along with innate immune stimulation [23,24]. However, hope that the resulting TEX antigen-based vaccines are promising immunotherapeutic tools has been dampened by evidence showing that TEX interfere with immune response induction [5,25,26]. Here, we review both the immune stimulatory and suppressive effects reported for TEX as well as current directions for applied uses in cancer immunotherapy. However, some additional background on cancer vaccines and the roles exosomes have played (and continue to play) there may be insightful.

2.2. Dendritic Cell-Based Cancer Vaccines

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) [27] that likely have functions and roles beyond their initial identity [28]. DCs are capable of uptake and digestion of potentially antigenic materials, along with the display of peptide antigens via MHC-I and MHC-II routes (to CD8+ and CD4+ T cells, respectively), and contributing appropriate co-stimulatory molecules to activate antigen-specific T cells via the “immunological synapse” [29]. Conceptually, one could generate and culture ex vivo DCs from a patient (or mouse), apply (“pulse”) sources of antigens to the DCs in culture, induce or allow the processing and presentation of antigens, and then return the DCs to the subject to in vivo stimulate antigen-specific T cells. The T cells should then undergo expansion, migrate to the periphery, and be available for tumor destruction. This has been a clinical paradigm for well over a decade [30], with over 2000 patients treated with such vaccines, and Phase III trials in four different disease sites currently underway [30]. Sipuleucel-T (patient DCs pulsed with prostatic acid phosphatase as an antigen fused to granulocyte-macrophage colony-stimulating factor as an immune stimulant) was the first cancer vaccine approved by the US Food and Drug Administration (FDA) [31]. There are a number of challenges involving DC-based cancer vaccines including production issues necessary for uniformity in phenotype and activity (the realm of good manufacturing practice—GMP) [32]. There are current questions as to what are the optimal means for generating DCs from precursors, as well as how to (or whether to) “mature” the cells, along with their preservation and re-growth after freezing [30]. Additionally, the nature of the loaded antigenic material (source, format, single vs. multiple antigens, etc.) likely plays a critical role in the final vaccine formulation, but there is no true consensus [33]. As these DCs are usually injected back into a patient, migration of the DCs to lymph nodes is another area of concern [34,35]. Finally, despite the activation of tumor-specific T cells from the DC vaccine, the local tumor microenvironment contributes heavily to immune suppression at multiple levels [36–39]. This also takes the form of systemic immune suppression [40–43], possibly driven by TEX [5,26,44,45].
3. Exosomes as Potential Vaccine Candidates (All Hands on DEX)

During the late 1990s/early 2000s, the idea of exosomes as putative cancer vaccines was making headway in pre-clinical and, eventually, clinical settings. This is because exosomes are surrogates of the cells that release them, and perhaps could elicit similar immune responses as could the parental cells themselves. The generation of DEX, dendritic cell exosomes, is shown in Figure 2. As cell-free versions of DC vaccines, one could presumably derive DEX vaccines by collecting the media from antigen-pulsed DCs and isolating the exosomes. In theory, the DEX could likely be stored, thawed, and utilized more efficiently than could the DCs themselves. It was known that professional antigen-presenting cells (APCs) such as B cells could release vesicles capable of antigen stimulation of T cells [46]. Following that publication, DEX from antigen-pulsed DCs were used as cancer vaccines in mice bearing relatively immunogenic (P815) and poorly-immunogenic (TS/A) syngeneic tumors. The anti-tumor responses were presumed to be T cell–dependent (there was no effect on tumor growth if the DEX were utilized in athymic/nude mice models), there were tumor-specific CTL responses generated, and the DEX were perhaps even more effective than the DC vaccines themselves [47]. Follow-up studies included a molecular characterization of DEX, identifying such proteins as MHC Class I and II molecules, co-stimulatory molecules such as CD86/B7.2, potential surface-binding proteins MFGE8, MAC1, and CD9, and an enrichment for the heat shock protein HSC73/HSPA8 [48]. The latter might be regarded as a “danger signal” for innate immune stimulation [49–51].

As to the mechanism of the DEX-generated immunity, the concept of exosomes as cellular surrogates suggested that DEX would have properties of DCs, and would be able to drive T cell responses in a similar fashion (e.g., antigen presentation and co-stimulation) [47]. Other studies suggested that this was not true, in that cells expressing a specific MHC II with display of an antigenic peptide released exosomes that were poor direct stimulators of T cells, but were effective stimulators if applied to DCs that were then exposed to the T cells [52]. The transfer of the MHC II/peptide complex occurred from the exosomes to the DCs, and it is speculated that there may be a similar transfer of MHC II to follicular DCs by B cells (although these vesicles appear to reside on the follicular DC surfaces). It was speculated that such vesicles may be important in guiding antigen-specific T cells into germinal centers for further B cell development [53]. This was further shown in a system with MHC II–displayed antigen using DCs that lacked MHC II expression; MHC II/antigen complexes were transferred from “wild-type” DCs to the MHC II–deficient DCs via exosomes, and those latter DCs could stimulate T cell-specific responses [54]. Additionally, this was shown to be the mechanism for MHC Class I—displayed peptides via transfer from DEX to endogenous DCs [55]. However, there remains the possibility that DEX can directly stimulate T cells, but this was typically considered a weak response [56]. Similarly, T cell stimulation required specific parameters on the vesicles derived from Drosophila cells used as model APCs (high-density display of MHC, presence of co-stimulator B7, and adhesion protein ICAM1), and the in vivo results did not rule out interaction with endogenous DCs [57]. Further work demonstrated that membrane vesicles derived from sonicated DCs could directly stimulate T cells, bypassing DC intervention, at least in vitro, but again, vesicle-DC interactions could not be ruled out in vivo [58]. The concepts of DEX/T cell and DEX/DC interactions are diagrammed in Figure 3.
Figure 2. Formation of “DEX” (dendritic cell exosomes, dexosomes). Dendritic cells (DCs) are professional antigen-presenting cells capable of antigen uptake/internalization which leads to presentation of antigens (peptides) on MHC Class I and Class II molecules. This contextual presentation of putative peptide antigens to (respectively) CD8+ and CD4+ T cells requires the addition of co-stimulatory molecules (e.g., CD80/86) to fully mature and activate the T cells. As shown, potentially antigenic proteins (green rectangle and purple oval) and peptides (green and purple small box versions) are loaded (“pulsed”) onto the DCs. Some of the peptides may directly bind to MHC molecules. During aforementioned endocytic events, proteins/peptides, MHC molecules, and co-stimulatory molecules (among other things) are internalized and enter antigen presentation and endosomal processing pathways. Following routes described in Figure 1, MVB formation and the release of DEX lead to extracellular vesicles with MHC molecules and co-stimulatory molecules on their surfaces, along with intracellular proteins that may be antigenic as well.

The use of DEX in tumor vaccine scenarios had been proposed multiple times (there are far more review articles than trial reports) [59–63], and clinical-grade DEX preparations had been described [64], thus leading the way for clinical trials. Results from one such trial [65] for patients with Stage IIIB/IV non-small cell lung carcinoma (NSCLC) treated with DEX loaded with MAGE3/4/10 peptides showed the DEX vaccines were well tolerated, and some patients demonstrated minor immune responses via delayed-type hypersensitivity (DTH) analysis and in vitro assays, with more significant responses seen in natural killer (NK) cell activity. While three of the patients had progressive disease prior to DEX treatment, two patients with stable disease incoming were progression-free 12 months after treatment. Another DEX cancer vaccine trial [66] for patients with Stage IIIB/IV metastatic melanoma reported
excellent safety profiles, with one objective response, one minor response, and two disease stabilizations noted. The DEX in this case were derived from DCs pulsed with MAGE3 peptides for both MHC I and II, as well as the DEX themselves receiving direct MAGE3 peptide loading. In both of these trials, the lack of potent T cell responses, but the promotion of NK cell numbers and activities [67], suggested that these could be areas for future engagement for DEX vaccines, along with attempts to repress the tumor-induced immune suppression [68]. However, a recent DEX vaccine trial for patients with advanced squamous cell carcinoma of the esophagus, where DEX were obtained from SART1 peptide-pulsed monocyte-derived DCs, did show enhanced T cell responses via ELISPOT assays, although the clinical responses were not spectacular [69]. The modulation of DEX by the ligand expression and maturation state of DCs, by the antigen-loading of DCs, and by the use of chemotherapies to suppress regulatory T cells (Tregs) are strategies employed in an ongoing DEX vaccine trial for patients with NSCLC [70]. These clinical trial results suggest that DEX may be a viable cancer vaccine strategy in terms of feasibility of preparation, ability to deliver multiple doses, and satisfactory safety profiles. As was true of most cancer vaccination scenarios of the times, no outright attempts were made to control or mitigate tumor-induced immune suppression, which will likely play important roles in future cancer vaccine trials [71].

**Figure 3.** Interactions of DEX with T cells and dendritic cells. (A) While there is speculation and some evidence (in an artificial system *in vitro*) that DEX may directly interact with and present antigen to T cells, it is not clear that this happens *in vivo*. Instead, DEX are believed to stimulate DCs (B) to cause them to be better antigen-presenting cells (with increased density of surface MHC and co-stimulatory molecules, as well as cytokine output). It is also possible that DEX may adhere to DC surfaces and directly present antigenic peptides in the context of MHC molecules.
One point of interest that will recur in our analyses of tumor exosome (TEX) vaccines is that B cell involvement may play important roles in anti-tumor efficacy. This was also demonstrated in animal models of DEX vaccines, where DEX from DCs were pulsed with whole ovalbumin (OVA) protein as a model antigen, or with OVA SIINFEKL peptide, which binds to the murine H-2K\(^b\) MHC I haplotype. Whole OVA protein generated better in vivo CD8\(^+\) T cell responses, as opposed to the SIINFEKL peptide; those CD8\(^+\) T cell responses were both CD4\(^+\) T cell- and B cell-dependent [72]. This led to better tumor growth control and increased overall survival of mice challenged with OVA-expressing tumors. In that context, the use of B cell-deficient mice reduced CD8\(^+\) anti-SIINFEKL responses (and it was known that CD4\(^+\) T cells were essential for the CD8\(^+\) activity). The suggestion was that B cell regulation of CD4\(^+\) T cells was critically important in optimal CD8\(^+\) T cell effector function.

While most research in exosome-based immune effectors centers on T cells and NK cells (and to some extent, B cells), Gehrmann et al. [73] looked at the impact of the CD1d display of the ligand \(\alpha\)-galactosylceramide (\(\alpha\)-GC) on DEX. CD1d is a non-classical MHC-type molecule that presents lipid antigens to effector cells, in this case invariant natural killer T (iNKT) cells (also called Type 1 or classical NKT cells). These cells express an invariant T cell receptor \(\alpha\) chain as well as natural killer cell markers, and they respond to glycolipid antigens presented by the CD1 family of molecules. In this study, murine DCs were pulsed with OVA, or with SIINFEKL peptide, and/or \(\alpha\)-GC. DEX from those DCs could activate iNKT cells as well as gamma-delta (\(\gamma\delta\)) T cells (another unconventional T cell family with a restricted T cell receptor repertoire). The combination of these enhanced innate immune effector activities led to increased CD8\(^+\) T cell responses and also boosted CD4\(^+\) T cell and B cell responses with notable overall anti-tumor activity.

An obvious drawback to DEX vaccine scenarios is the need for autologous DC cultures, which, as mentioned above, have inherent limitations and cannot be truly “off-the-shelf” products. Non-autologous or allogeneic cell-based vaccines have been clinically utilized for some time [74], and one could imagine a similar approach for DEX. Umbilical cord blood DCs loaded with tumor antigens, and DEX from those cells, have been proposed as potentially useful sources for such cell- or DEX-based vaccines [75]. Another extension of this is a system called CELLine 1000 to generate DEX; in one publication [76], a cancer vaccine formulation called chaperone rich cell lysate (CRCL) [77–80] was used as the antigen source in a murine brain tumor model. Curiously, CRCL has strong proteomic overlaps with exosomes, and has a novel structure that may lead to similar DC responses as TEX [81]. In a similar set of experiments, but using syngeneic DEX from CRCL-pulsed DCs in the same murine brain tumor model, those DEX drove CBL (Cbl proto-oncogene, E3 ubiquitin protein ligase) and CBLB (Cbl proto-oncogene B, E3 ubiquitin protein ligase) signaling with AKT (protein kinase B) and ERK (extracellular regulated kinase) signaling in stimulated T cells [82].

One interesting point behind the putative value of DEX as vaccines may actually involve impacts of DEX directly on tumor cells. The transfer of antigen-based stimulatory and co-stimulatory molecules from DEX to tumor cells would lead to better T cell reactivity against the tumor in ways that are alternative to DC-based stimulation of T or NK cells [83]. This is a novel application of DEX in terms of directly modifying tumor cells to make the tumor more amenable to immune attack.
4. TEX as Anti-Cancer Vaccines

4.1. Stand-Alone TEX

Not long after the pre-clinical DEX cancer vaccine reports were published, the use of TEX was reported as a potent source of immunogenic targets in murine tumor models TS/A, P815, and MC38 [84]—including the ability of TEX from one tumor to cross-prime antigens that led to rejection of the other tumor type (with a different MHC background). This strongly suggested that tumor-derived exosomes contained antigenic material, and could passage common or shared antigens into appropriate antigen presentation pathways of recipient APCs. In the case of the allogeneic cross-protection model, the transfer of presumably membrane-bound MHC/peptide complexes from exosomes to APCs was not considered to be a mechanism, in contrast with what had been shown for some of the DEX studies [52,54,55]. Further, using human melanoma cells as exosome sources, the authors showed the presence of full-length tumor antigen MART1/MLANA, and DCs pulsed with those TEX could present antigens to stimulate MART1-specific T cell clones. TEX-derived antigen delivery and presentation by recipient DCs is shown in Figure 4. A summary of TEX vaccine publications is in Table 1.

After that initial TEX-based vaccination publication, others soon followed, including one utilizing murine plasmacytoma TEX in a vaccination setting that generated protective T cell-based immunity, and demonstrated the presence of known tumor-specific antigens (IAP (intracisternal A particle) gag-related structural protein p73, and tumor rejection antigen P1A (Trap1a)) [85]. TEX were clearly important sources of tumor antigens and immune stimulus in several models, including in vitro work with human immune cells and human tumor-derived TEX [86]. This article also made a salient point about the source of TEX—for most murine models, one acquired TEX from tumor cell culture-spent medium, which would seem an unlikely source for personalized treatment of human tumors. The authors proposed that ascites fluid (an unfortunate outcome from several cancer types) could serve as sources of TEX for patients afflicted with ascites. However, for tumors that did not have associated ascites accumulation, there are not many obvious biofluid sources of TEX. One potential means around this issue could be to prepare exosome-like nanovesicles from solid tumor sources by sonication of single cell suspensions followed by density-gradient centrifugations [87].

Despite the conflicting evidence as to their in vivo immunomodulatory role that began to appear about the same time (see below), TEX have been shown to be potent anticancer vaccines in animal models, driving antigen-specific T cell and B cell responses. Below we highlight some of the works involving unmodified TEX in cancer immunotherapy.

Various publications highlighted the use of TEX as cancer vaccines in animal models, simply using TEX harvested from cell culture–spent supernatants without any modifications or manipulations. This was shown for the leukemia model [88] in a prophylactic setting where increased CTL activity was noted. In an overlap with the heat-stress modalities (see below), it was determined that heat-shocked murine brain tumor cells release heat shock proteins and exosomes that were likely responsible for tumor eradication if those stressed cells were implanted as tumors [89]. Following that, TEX from (unstressed) cells were shown to have HSPs on their surfaces, along with known tumor antigens (EGFRvIII, GPNMB), as well as transforming growth factor beta (TGFβ). These TEX were potent vaccines driving T and B cell responses in a prophylactic setting, but had no impact in a stringent (intracranial), pre-established tumor setting [90].
Figure 4. Tumor exosomes (TEX, texosomes) and their interactions with dendritic cells. (A) Shows a hypothetical texosome with a potential surface antigen, innate stimulatory molecules such as high mobility group B1 (HMGB1), and heat shock proteins (HSPs, both surface and interior, including those with bound peptides (yellow dot)). Also possibly present might be MHC molecules (generally Class I) with peptide antigens displayed, and other proteins (green and brown ovals) as well as nucleic acids such as RNAs. Potential routes of interactions and transfer or internalization of vesicle contents are shown in (B). Part a depicts endocytic means of internalization (as mentioned in Figure 1) by numerous mechanisms. Part b is the result of direct membrane fusion between TEX and the DC, transferring intravesicle components into the cell interior while depositing vesicle membrane proteins and lipids on/into the DC plasma membrane. Part c shows “docking” of the TEX on the surface of the DC without apparent internalization. This would allow stimulus of the DC with presentation of TEX antigens in the context of TEX MHC molecules, as shown on the other side of the cell. Exosome/extracellular vesicle uptake by recipient cells is reviewed here [91]. Processing of the TEX-derived antigens yields TEX peptides on MHC I and MHC II molecules (presenting to CD8+ and CD4+ T cells, respectively), along with enhanced output of co-stimulatory molecules for more effective T cell priming. It is also conceivable that mRNA from TEX could be translated in the DC to generate tumor antigens for presentation as well.
Table 1. Summary of TEX as vaccines.

| Reference          | Tumor Type                                              | TEX (Mod/Engin) | Vax Route | Adjuvant/Stimulus | Outcome                                      | Notes                        |
|--------------------|---------------------------------------------------------|-----------------|-----------|-------------------|----------------------------------------------|------------------------------|
| Wolfers et al., 2001 [84] | TS/A; MC38 (mouse)                                      | TEX only        | SC/ID     | None              | Autologous and alloogeneic cross protection DC presentation of XO Ags | CD4+ and CD8+ dependent     |
|                    | L1210; AK7;                                              |                 | or TEX on DCs |                   |                                              |                              |
|                    | Ba/F3; (mouse)                                           |                 |           |                   |                                              |                              |
|                    | Fon; Mel-888 (human)                                     |                 |           |                   |                                              |                              |
| Altieri et al., 2004 [85] | J558; MPC11; Colon 26 (mouse)                        | TEX only        | SC        | None              | Prophylactic and rechallenge protection      | Tumor-specific CTLs active  |
| Bu et al., 2006 [88] | L1210 (mouse)                                           | TEX only        | SC        | None              | Prophylactic protection                      | CTLs active                 |
| Graner et al., 2009 [90] | SMA-560vIII (mouse)                                    | Prophylactic and rechallenge protection |           |                   |                                              | B, T cells active           |
| Hao et al., 2006 [92] | EG7/OVA (mouse for Exos)                                | EG7 TEX; DEX    | IV        | None              | DEX > TEX vs. Metastatic disease (prophylaxis) | DEX > TEX CTL activity      |
|                    | B16-OVA (mouse tumor target)                            | from OVA-pulsed DCs |           |                   |                                              |                              |
| Gu et al., 2015 [93] | WEHI3B; RENCA (mouse)                                   | DEX pulsed with TEX as vax | SC       | None              | DEX/TEX > DEX/lys for preventing tumor growth/overall survival | Increase CTL and NK activity |
| Dai et al., 2005 [94] | LS-174T (CEA+, human)                                   | TEX from cells +/- heat shock | SC       |                   | HS TEX from CEA+ cells > anti-tumor responses | Increase CD4+/CD8+ activity |
|                    | SW480 (CEA+, human)                                     |                 |           |                   |                                              |                              |
|                    | LoVo (CEA+, human)                                      |                 |           |                   |                                              |                              |
|                    | A549 (CEA-, human)                                      |                 |           |                   |                                              |                              |
|                    | (mice txg for HLA-A2.1)                                 |                 |           |                   |                                              |                              |
### Table 1. Cont.

| Reference               | Tumor Type                          | TEX (Mod/Engin)                      | Vax Route | Adjuvant/Stimulus          | Outcome                                                                 | Notes                                                                 |
|-------------------------|-------------------------------------|--------------------------------------|-----------|----------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------|
| Cho et al., 2009 [95]   | CT26-MUC1; B16-MUC1 (mouse)         | TEX from cells +/- heat shock         | ID        | CPG (anti-tumor)           | HS TEX > auto/allogeneic anti-tumor responses                           | HS TEX > B and T cell responses                                       |
| Xie et al., 2010 [96]   | J558 (mouse)                        | TEX from cells expressing HSP70 on surfaces | SC        | None                       | TEX70 > TEXhs > TEX in anti-tumor assays                               | Increase CD4+, CD8+, NK responses                                    |
| Chen, et al., 2011 [97] | Lewis lung carcinoma (3LL, mouse)   | TEX from cells +/- heat shock         | IT, SC    | none                       | HS-TEX > TEX in anti-tumor assays                                      | HS-TEX contain chemokines, attract DCs and T cells                   |
| Yang, et al., 2007 [98] | EG7/OVA [IL2 tfxt for TEX] (mouse)  | TEX w/IL2                             | SC        | none                       | TEX-IL2 > TEX + IL2, TEX in anti-tumor assays                           | CD8+ > CD4+ > NK effectors                                           |
| Xie et al., 2010 [99]   | J558 (mouse, P1A Ag) tfxt to express TNFA, IL2, IFNG | TEX from each transfectant            | IV        | none                       | TEX/TNFA > TEX.IIL2 > TEX/INF in anti-tumor assays                     | Same order for P1A-specific CTL                                     |
| Lee et al., 2011 [100]  | B16F1 (mouse)[CIITA tfxt for TEX]   | TEX w/CIITA                           | ID        | none                       | TEX/CIITA > TEX in in anti-tumor assays                               | TEX/CIITA > TEX for DC, T cells, B cells                             |
| Rountree et al., 2011 [101] | CT26-PAP; E6-PSA (mouse, expressing human Ags) | Immunize w/virus to drive PAP or PSA exo expression linked to C1C2 lactadherin domain | SC (virus) | none                       | Ag/C1C2 > untargeted Ag in anti-tumor assays                           | Similar responses in B cell and T cell assays; B cells were strain-dependent |
| Reference                  | Tumor Type               | TEX (Mod/Engin)                                      | Vax Route | Adjuvant/Stimulus | Outcome                                                                 | Notes                                                                 |
|---------------------------|--------------------------|------------------------------------------------------|-----------|-------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------|
| Zeelenberg et al., 2011 [102] | MCA101-OVA (mouse)       | cells transf for soluble OVA, membrane OVA, or TEX-OVA (via C1C2) | cyroablation | none              | TEX-OVA > sOVA > fcOVA tumors for immune activation and anti-tumor response |                                                                      |
| Sedlik et al., 2014 [103]  | MCA101-OVA, EL4-OVA, B16F-OVA (all mouse, expressing OVA) | cells transf for gag-OVA or C1C2-OVA (DNA vaccine) | ID, IM electroporation | none              | both vax had ~ equal benefit in anti-tumor and cellular responses       |                                                                      |
| Hartman et al., 2011 [104] | 4T1--HER2 (mouse, human HER2) | C1C2-CEA, C1C2-HER2 (ECDs fused to C1C2) AdVir vaccine | ID         | none              | C1C2-HER2 > ECD-HER2 in anti-tumor responses                              | C1C2-Ag > ECD-Ag for B and T cell responses                           |
| Zeelenberg et al., 2008 [105] | MCA101-OVA (mouse)       | C1C2-OVA, solb OVA (DNA vaccine)                     | IM        | none              | C1C2-OVA > sOVA in anti-tumor response                                   | C1C2-OVA > sOVA in T cell responses                                  |
| Xiu et al., 2007 [106]     | EG7 (OVA) (mouse)        | TEX with SEA or TM-SEA “transfer”                    | SC        | none              | TEX/TM-SEA > TEX/SEA > TEX > SEA in anti-tumor responses               |                                                                                                                                |
| Dai et al., 2008 [107]     | CRC with ascites          | AEX (TEX from ascites in sera)                        | SC        | some GM-CSF; various chemos 1 pt w/stable disease 1 pt w/minor response | AEX+GM-CSF > AEX for DTH and anti-CEA T cells                        |                                                                                                                                |

Table 1. Summary of TEX as cancer vaccines. Abbreviations: OVA = ovalbumin; TEX = tumor-derived exosomes; SC = subcutaneous; IM = intramuscular; ID = intradermal; IV = intravenous; IT = intratumoral; DC = dendritic cells; XO = exosomes; IFA = incomplete Freund’s adjuvant; IL2 = interleukin 2; INFγ = interferon gamma; TNFα; tumor necrosis factor alpha; CIITA = class II major histocompatibility complex, transactivator; ECD = extracellular domain; SEA = staphylococcal enterotoxin A; TM = transmembrane; GM-CSF = granulocyte-macrophage colony-stimulating factor; PAP = prostatic acid phosphatase; PSA = prostate-specific antigen; CRC = colorectal cancer.
In a comparison between DEX and TEX as forms of immunotherapy, Hao et al. [92] used EG.7 cells (OVA-expressing tumor as a model antigen) as sources of TEX vaccines, and compared immune parameters to mice immunized with DEX from OVA-pulsed DCs. DEX drove greater in vitro expansion and cytotoxicity of T cells from treated mice, as well as better overall anti-tumor immunity, but that effect was seemingly reliant on OVA as the antigen (the in vivo tumor model was a different OVA-expressing tumor). Other tumor-specific antigens from EG.7 would likely not be relevant in the B16-OVA model used. B cell/antibody induction did not appear to be measured. Curiously, the exosomes were delivered intravenously (IV), which likely impacts how and which immune cells encounter the exosomes (see below).

Rather than injecting TEX directly for presumed APC interaction, TEX have been used as immunogens for DC loading. Using murine leukemia and renal cell cancer models, TEX as immunogen sources proved superior to tumor lysate for promoting DC-driven anti-tumor immunity. TEX-loaded DCs showed persistence of TEX (and presumably TEX products) in DC MHC II-containing compartments. Those DCs provoked more trogocytosis (exchange of DC surface materials to T cells). The persistence and localization of TEX/TEX material within DCs were suggested as mechanisms for the improved anti-tumor efficacy [93].

4.2. TEXing while Driving Immune Responses: Manipulations of Cells to Produce TEX with Enhanced Immune Properties

Manipulation of the cells producing TEX could potentially lead to TEX that are more efficient at driving immune responses. This has been configured in multiple ways and several examples are illustrated below.

4.2.1. Heat Shock, Cell Stress, HSPs, and TEX Effects

One means of potentially generating enhanced immune responses is to increase “danger signal” expression via increased heat shock protein expression. As noted above and elsewhere [108,109], HSPs, particularly those exposed on cell surfaces or released extracellularly, can ameliorate innate immune responses, leading to heightened adaptive responses. Dai et al. [94] heat stressed murine tumor cells expressing human carcinoembryonic antigen (CEA) in a transgenic (human MHC) model, demonstrating that TEX from the heat-shocked cells drove better anti-tumor immunity compared to TEX from untreated cells. In another setting [95], TEX from heat-shocked, MUC1-expressing tumors of different MHC haplotypes (CT26 and B16) were better than control TEX at inducing anti-tumor immune responses in both syngeneic and allogeneic settings (i.e., treating mice with TEX from heat-shocked CT26 cells to reject B16 tumors). HSPs, especially HSP70, were considered to be important players in the Th1 polarization of lymphocytes. This paper also demonstrated increased antibody output against the injected exosomes, along with [90], among the first to point this out. In another iteration, the group utilized an engineered membrane HSP70 that localized to TEX surfaces (along with the P1A tumor antigen in a myeloma model). These TEX were taken up by DCs, which in turn matured and were effective at inducing CTL responses against P1A-expressing tumor cells (TEX and DC + TEX were also used as prophylactic vaccines). It was found that NK cells played prominent roles in the anti-tumor response [96]. Furthermore, TEX from heat-stressed Lewis lung carcinoma cells proved effective at
attracting and activating DCs, along with T cells, and drove profound tumor regression upon intratumoral injections. The HS TEX contained the chemokines CCL2, 3, 4, 5, and 20, which associated with lipid raft components following hyperthermia treatments [97]. Further speculation suggests that either whole-body hyperthermia or localized treatments may lead to TEX release as another form of “self-vaccination” [110].

Chemotherapy agents also induce stress programs, such as the heat shock response [111], which ordinarily favor tumor survival. However, TEX displaying surface HSPs following drug treatment of hepatocellular carcinoma cells were potent stimulators of NK cell activation and cytotoxicity in vitro [112]. This suggests that chemotherapies may be able to induce a “self-vaccination” phenomenon with TEX HSPs as NK cell triggers. Similar results were obtained treating hepatoma cells with a histone deacetylase inhibitor [113]. On the other hand, some speculate that such TEX could potentially serve as decoys, leading to ineffective NK cell responses (including downregulation of activation receptors and upregulation of inhibitory receptors) [114].

4.2.2. Engineering the Parent Cells—The TEX of New Immune Ideas

Modification of tumor cells to make them more immunogenic and therefore potentially useful vaccine material has long been a goal in cancer immunotherapy [115]. The concept of using TEX from modified tumor cells as surrogate vaccines was a logical next step. Genetic introduction of interleukin 2 (IL2) into EG.7 (ovalbumin-expressing) tumor cells resulted in the presence of IL2 in (or on) TEX from those cells. When used as vaccines in both prophylactic and pre-established tumor settings, the IL2-containing TEX were more effective than unmodified TEX or TEX mixed with IL2; CD4+, CD8+, and NK cells were all involved in the anti-tumor immunity [98]. To perhaps better ensure membrane expression of IL2, T24 human bladder cancer cells (expressing the tumor antigen MAGE1) were transfected with a construct that linked IL2 to a glycosyl-phosphatidylinositol (GPI) anchor resulting in membrane display on the cells and apparently on the TEX as well. These GPI-IL2 TEX stimulated DCs more efficiently to generate specific CTL responses against T24 cells in vivo [116].

In a more extended version of immune gene manipulation of tumor cells, the aforementioned P1A-expressing myeloma cells were transduced to express TNFA, IL2, or IFNG, and TEX from those cells (and unmodified controls) were used in an IV vaccination scenario. TEX from TNFA-transduced cells were superior in both tumor protection and increasing P1A-specific CTLs [99].

To induce increased CD4+ T cell responses (hopefully leading to better CD8+ T cell responses), one group transduced murine B16 cells with the Class II transactivator (CIITA) gene, leading to higher MHCII display on TEX. Pulsing DCs with CIITA TEX strongly activated DCs, resulting in better T cell and B cell activation in vitro and in vivo, along with improved anti-tumor activity (intradermal vaccination) [100].

Further use of engineered cells producing TEX as a means of antigen loading of DCs involved the use of a lymphoblastoid “cell factory” transfected with HER2 (ERB2/EGRF2). TEX from those cells efficiently transferred ERB2 peptides to MHC I and MHC II displayed on DCs that could stimulate CD8+ responses from cells in the blood of ERB2+ cancer patients [117].
4.2.3. Exosome Display—Filling the TEX Box

Genetic manipulation of parental cells to enhance TEX immunogenicity relies on the possibility that such cellular alterations lead to changes in the TEX. The concept of “exosome display technology” [118] employs directed targeting of potential tumor antigens for incorporation into exosomes as cargo. In one example, a vaccinia virus construct was used to fuse prostate-specific antigen (PSA) or prostatic acid phosphatase (PAP) to the C1C2 (exosome-targeting) domain of lactadherin. Mice prophylactically immunized with the exosome-targeted versions of the prostate cancer antigens had better anti-tumor responses (including activated T cells and serum antibody responses) than did mice immunized with the same vaccinia platform where the antigens were not specifically exosome-targeted [101]. Exactly what cell types, and which exosomes from the presumably immunized cells, provoked the immune responses were not determined. These results were recapitulated to some effect in a setting where OVA tumor antigen localization was controlled to secreted, membrane (cell)-bound, or TEX-targeted. Vesicle-targeting of OVA again resulted in prominent antibody and T cell responses leading to greatly reduced tumor growth and activated CD8+ T cells (following tumor cryoablation) [102]. Other versions of “exosome display” targeted OVA via a DNA plasmid vector vaccine to either exosome external surfaces (via lactadherin C1C2 domain) or to the interior surfaces (via a viral Gag construct) [103]. From an overall tumor rejection perspective (vaccinations done by intramuscular and/or intradermal injection and electroporation), there were essentially no differences between the two constructs, but the C1C2 linkage generated more active CD4+ T cells, and an IgG1 vs. IgG2b shift in antibody output, at least at lower vaccine dosages.

Using a different vector, adenovirus constructs with extracellular domains of CEA or HER2 targeted to exosomes (via lactadherin C1C2 domain) again produced specific T cell and antibody responses, to some extent even in antigen-tolerant animal models, with subsequent improved tumor rejection in the HER2 model [104].

Another report pursued engineered membrane expression of OVA (in a murine MCA (methylcholanthrene-induced) sarcoma model) that led to its localization in exosomes as cargo [105]. The presence of the antigen in vesicles in the membrane-bound form resulted in a lymphocyte-dependent reduction in tumor growth kinetics, as if the tumor could “self-vaccinate”.

4.2.4. Altering TEX Directly—New Immune Fonts

Another means of modification would be to directly alter the TEX. In one instance [106], superantigen staphylococcal enterotoxin A (SEA) was physically tailed with a hydrophobic segment that allowed its incorporation into exosomes from EG.7 tumor cells, presumably as a transmembrane protein (SEA-TM). As prophylactic vaccines, these SEA-TM TEX proved to be more effective CD8+ inducers and were overall better in reducing tumor burden than SEA-modified TEX or parental EG.7 TEX.

4.2.5. Clinical TEX: Use in a Clinical Cancer Vaccine Trial

As DEX had been used in clinical trials (see above), TEX cancer vaccines were expected to follow suit, including a position paper essentially describing the putative combination of chemotherapies and immune agonists for use in treating patients with ovarian cancer [119]. Following the aforementioned
use of ascites fluid–derived TEX as sources of autologous antigens, early works demonstrated the presence of known tumor antigens from TEX collected from various malignant effusions, ascites in particular, that could be presented by DCs to specific T cells [120]. A guide for clinical-grade TEX preparations was developed, along with suggestions for adjuvants [121], but nothing seemingly matriculated for the next couple of years. Eventually there was a clinical trial performed in China [107] where TEX were harvested from ascites fluid of 40 patients with colorectal cancer (the TEX were termed AEX) and were used for autologous vaccinations with or without GM-CSF. Patients were of HLA-A*0201 haplotype, and had CEA detectable in sera. Patients were subcutaneously injected with 100, 200, 300, or 500 μg of AEX for a total of four vaccinations, and half of the patients received 50 μg of GM-CSF per vaccination. Patients all had DTH responses at doses of 300 μg AEX or greater, but required GM-CSF for significant differences at 200 μg AEX. Using CD8+ T cells isolated from the DTH sites, tetramer responses (vs. CEA), along with IFNG release and cytotoxicity driven by CEA+ cells, were significantly increased in patients receiving AEX + GM-CSF. Safety and tolerability were very good, although no outstanding clinical responses were noted. To our knowledge, these are the only published clinical results from a TEX-based cancer vaccine trial. The trends of TEX in immune responses had shifted from TEX as immune stimulators to TEX as immune suppressors, and we will examine some of those studies in the next section.

5. TEX in Immune Suppression

TEX certainly have immune-suppressive attributes, and these have been reviewed extensively [4,44,114,122–125]. Here, we will briefly discuss some aspects of TEX immunosuppression as it relates to T, B, and NK lymphocytes as well as monocytic cells.

5.1. “Bad” TEX: Vessels of Tumor-Induced Immune Suppression of Lymphocytes and Monocytes

5.1.1. T Lymphocytes

Around the same time that TEX were considered to be cancer vaccine candidates, further examination was finding that TEX had immune suppressive qualities as well, including the ability to promote induction of apoptosis and signaling defects in lymphocytes [8,126,127]. The apoptotic effects were likely FAS ligand-driven [128], and possibly PD1-L driven [129], but this is not seen in all cases [26]. The effects of TEX surface CD39 and CD73 lead to an ectonucleotidase cascade that generates extracellular adenosine, which has suppressive T cell effects [130]. TEX have also been shown to impair lymphocyte responses to IL2 [131], and to promote activation and expansion of regulatory T cells (Tregs) that are themselves immune suppressive [132]. Again, this is not universally seen [26].

5.1.2. B Lymphocytes

While there is not an extensive literature on TEX effects on B cells, circulating TEX can conceivably interact with therapeutic antibodies injected into patients based on surface-displayed antigens, which can reduce antibody-dependent cellular cytotoxicity (ADCC) [133]. TEX from B cell lymphomas display CD20, and thus shield target cells from the therapeutic antibody rituximab; these TEX can fix and consume complement to prevent complement-dependent cytotoxicity (CDC) as well [134]. Given that
TEX are potent generators of serum antibodies, and are known to display numerous tumor-related antigens [90,135], it is possible that TEX could be substantial decoys for exogenous or endogenous anti-tumor antibodies that could essentially titrate out such immune effector molecules.

5.1.3. NK Cells

The presence of NK cell (NKG2D) ligands such as MICA, MICB, and ULBP1/2 on TEX has been known for some time, and these ligands appear to be involved in TEX-dependent suppression of NK cell activity [136]. TGFβ, known to be present on TEX [90], seems to be a major culprit in that suppression [137,138]. One line of thinking is that the NKG2D ligands may downregulate the receptor on NK cells, thus reducing NK activity, or with such TEX acting as circulating decoys [139]. On the other hand, the presence of the inducible HSP70 on TEX surfaces is thought to be stimulatory to NK cells, resulting in anti-tumor activity [112,140,141]. It begs the question whether HSP70 as a surface ligand for NK cells could also make such TEX decoys against NK activity.

5.1.4. Monocytes, Macrophage, Dendritic Cells

TEX are known drivers of myeloid-derived suppressor cells (MDSC), monocytic cells of myeloid lineage that regulate functions of DCs, macrophages, T and NK cells [125]. TEX can block differentiation of myeloid precursors [142] and drive MDSCs from those cells, again via effects of TGFβ, and also prostaglandin E2 (PGE2) [143]. While TEX-surface HSP70 was considered stimulatory to NK cell activity (above), it seems to lead to generation of MDSC by TLR2/MyD88 stimulation and activation of STAT3 [144]. On the other hand, IV-injected TEX targeted to brain/lung macrophages, and upregulated pro-inflammatory cytokines via NFKB activation through TLR2 stimulation. Palmitoylated proteins on TEX surfaces led to NFKB activation [145]. This may or may not conflict with the induction of monocyte/macrophage M2 phenotypes (considered more tumor-promoting) by glioma TEX [146], but B16 TEX were regarded as inducers of DC maturation and CD4+ T cell stimulation, driving NFKB activation in RAW264.7 macrophage cells; however, those cells released a mixed bag of cytokines/chemokines with overall Th2/M2 phenotypes [147]. A summary of TEX (and DEX) interactions with various immune system cells is shown in Figure 5.

In addition to their immunosuppressive roles, TEX have been shown, in several cancer models, to actively promote tumorigenesis and metastases. Mechanisms for these actions include modulation of bone marrow progenitors, modification of sentinel lymph nodes, and transfer of oncogenic material including receptor proteins and RNA [148–150]. TEX have been shown to help establish the pre-metastatic niche through the creation of a suitable microenvironment for metastatic growth in distant sites [151]. Thus, while related to (suppressed) immunity, other functions of TEX benefit tumor growth and metastasis as well.
Figure 5. Summary of TEX and DEX interactions with immune cells. (A) depicts more extensive versions of TEX and DEX than previously shown (e.g., Figures 2–4), emphasizing NKG2D ligands MICA/B and ULBP1, and suppressive entities FASL and TGFB (on TEX), and stimulatory molecule IL15RA (IL-15 receptor alpha, on DEX). The rest of the figure shows possible (and perhaps conflicting) outcomes of TEX and DEX interactions with various immune cells. TEX and DEX interactions with monocytes (“Monos”), shown in (B), lead to a variety of outcomes depending on the recipient cells. Immature dendritic cells (DCs) may be activated to further maturation, resulting in immune (T cell) stimulation, or may be held in an immature state, which is largely considered suppressive. Macrophages (MΦ) are often stimulated, producing pro-inflammatory cytokines via activation of NFKB. However, TEX in particular may interact with undifferentiated monocytes to push them (often via
TGFB) into a monocyte-derived suppressor cell (MDSC) phenotype, producing immune suppressive factors TGFB and PGE2. B cells (C) may interact with TEX and DEX in ways that stimulate antibody (Ab) production; however, TEX are able to bind serum Abs via surface antigens and can titrate potentially tumor-reactive Abs out of the system. This results in reduced antibody-dependent cellular cytotoxicity (ADCC). Further, TEX can bind complement components and prevent complement-dependent cytotoxicity (CDC). As mentioned throughout the text, TEX and DEX interactions with T cells (D) may be stimulatory, activating naïve T cells (via DEX, although this is controversial), and possibly further stimulating previously activated T cells (via TEX). However, most TEX/T cell interactions are thought to be immune-suppressive, leading to generation of regulatory T cells (Tregs), anergic and deactivated phenotypes, and sometimes apoptosis, likely driven by FAS/FASL interactions. DEX interactions with natural killer (NK) cells (E) via the NKG2D ligand ULBP1, promoted by IL15RA, stimulate NK cells for pro-inflammatory cytokine secretion and enhanced perforin- and granzyme-mediated cytotoxicity. Interactions with TEX, however, are less clear; NKG2D ligands such as MICA/B, and TEX-surface HSP70 (interacting with NK cells via CD94) could be stimulatory, but often leading to down-regulation of NKG2D. TGFB also has suppressive influences resulting in decreased perforin release and general NK cell deactivation.

6. Immune Stimulation or Immune Suppression; Is It All in the ConTEXt?

From the preceding reports, it is clear that TEX both support and suppress immune responses against tumors. There is the obvious presence of tumor antigens and other immune-stimulatory molecules (e.g., HSPs) in and on TEX, and their virus-like particle character [152,153] suggests that exosomes could be useful vaccines, and this is borne out of the literature in this article. In other circumstances, preparation of nano-vaccines based on exosome characteristics should also be feasible [154–156]. On the other hand, the immune-suppressive features are also evident. Many of the challenges in determining which direction the immune response goes lie in in vivo systems that are, by definition, complicated. One thing that does not often receive sufficient attention is the route of injection (generally in animal models) leading to exosome trafficking. Most of the reports herein used subcutaneous or intradermal injections; we have noted above instances where other routes (intravenous, intratumoral) were used.

This has been reviewed recently to some extent, but has mostly focused on DEX and B cell-derived exosomes [157], which may influence which recipient cells encounter the exosomes and may also determine the responses to those exosomes. However, some principles likely apply, such as the rapid clearance of exosomes by the hepatic and splenic reticuloendothelial system (RES) following intravenous injection. This would be predicted based on known biodistribution of liposomes and other nanoparticles [158], but one might consider the possibility that appropriately stimulatory vesicles might be able to induce an effective immune response via the phagocytic APCs of the RES. On the other hand, as noted in [157], trafficking studies essentially rely on bulk exosome availability for detection; small exosome quantities would not be noticed in most cases. Thus, interactions with lymphocytes in the blood might escape notice, but would seem very likely in a tumor setting where there would be nearly continual release of exosomes into the blood, and at potentially high levels [26].
Intradermal/subcutaneous delivery seems to lead to uptake by CD11c+ DCs that eventually migrate to the draining lymph node [159]; another model found that CD8+ DCs were exosome recipients via the integrin LFA-1 (CD11a/CD18) [160]. These studies imply that dermal APCs are potentially extremely important in the initiation of TEX-induced immune responses leading to T cell activation.

The status of those APCs prior to vaccination is undoubtedly important, and may reflect a number of parameters such as overall stimulatory capacity of the injected TEX, quantity of TEX, and frequency of administration, etc. One critical parameter of TEX vaccination may be the systemic immune condition at that time. As mentioned above, if TEX are already in circulation, much data suggests there could be significant lymphocyte dysfunction [161]; this would likely abrogate effects of local APC stimulation of TEX vaccination (e.g., comparing the prophylactic immune response vs. that in the pre-established tumor setting [90]). Thus, one would preferably target skin/dermal APCs, but in the context of low or no tumor-induced immune suppression, locally or systemically. This situation may exist after tumor excision or by bulk reduction with chemo/radiotherapeutics, as that should remove the source of the immune-suppressive moieties. This would also depend on the half-lives of those immune-suppressive moieties. Some models, particularly those using exosomes as almost a form of immune accountancy (stimulus or deficit), may help to predict the status of immune activation vs. immune tolerance [162] or to determine states in the framework of a cancer-immunity landscape [163]. These would suggest that removal of tumor exosomes from blood would represent a parameter change that could allow for enhanced immune responses, and such devices are currently in a clinical trial [164] (NCT02215902, ClinicalTrials.gov).

Practical issues such as TEX sources may become important; as mentioned above, many tumors do not produce ascites fluid, which seems to be the current choice of autologous TEX. One may consider cell line sources of TEX; allogeneic cell lines as cancer vaccines exist and are in clinical trials [74,165]. As long as sufficient shared tumor antigens are present, along with relatively low quantities of immunosuppressive agents (e.g., TGFB), the allogenicity may actually prove beneficial. Engineering of cells producing TEX, and of TEX themselves (as mentioned above), could yield GMP-quality, off-the-shelf vaccine candidates relevant for numerous tumor types. With FDA approval of immune checkpoint inhibitors [166], potential combination therapies targeting both activation of immune stimulation and suppression of immune suppression are now viable modalities. The TEXual revolution may just be starting.

7. Conclusions

Exosomes are important mediators and regulators of immunity for which there is potential widespread therapeutic application. Although TEX natively immunosuppress and facilitate tumor progression, they are also important sources of tumor antigens, with potential clinical application in immune stimulation. This is the dichotomy of TEXual responses in cancer immunity. Initial studies in murine models show promising clinical responses to dendritic cell vaccines derived from TEX as opposed to other antigen sources. However, while preclinical studies show anti-tumor efficacy, in clinical trials the observed immunogenicity of such vaccines remains underwhelming in several studies. Various co-stimulatory molecules have been discovered, such as heat-shock proteins, which may have a further role to play in developing the optimal anticancer vaccine. In addition, some vaccine structural experiments demonstrate
differences in efficacy based on location and presentation of the vaccine antigens. It behooves future research to focus not only on development of tumor-derived exosome antigens for cancer vaccines but also to optimize the context in which they are presented to maximize the clinical response. Inhibition of immune suppression will also play a critical role in the development of TEX-based cancer vaccines, which may include preventing TEX effects on immune responders such as T and NK lymphocytes, but will focus TEX effects on APCs. Defining that conTEXt will be critical.

Acknowledgments

This work was supported by the University of Colorado Neurosurgery Department and National Institutes of Health 5-R01-EB016378-0.

Author Contributions

Both authors contributed to the writing, revising, and proofreading of the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. De Toro, J.; Herschlik, L.; Waldner, C.; Mongini, C. Emerging roles of exosomes in normal and pathological conditions: New insights for diagnosis and therapeutic applications. *Front. Immunol.* 2015, doi:10.3389/fimmu.2015.00203.

2. Yanez-Mo, M.; Siljander, P.R.; Andreu, Z.; Zavec, A.B.; Borras, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J.; et al. Biological properties of extracellular vesicles and their physiological functions. *J. Extracell. Vesicles* 2015, doi:10.3402/jev.v4.27066.

3. Benito-Martin, A.; di Giannatale, A.; Ceder, S.; Peinado, H. The new deal: A potential role for secreted vesicles in innate immunity and tumor progression. *Front. Immunol.* 2015, doi:10.3389/fimmu.2015.00066.

4. Greening, D.W.; Gopal, S.K.; Xu, R.; Simpson, R.J.; Chen, W. Exosomes and their roles in immune regulation and cancer. *Semin. Cell Dev. Biol.* 2015, 40, 72–81.

5. Hellwinkel, J.E.; Madsen, H.; Graner, M.W. Immune modulation by tumor-derived extracellular vesicles in glioblastoma. In *Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor*; Lichtor, T., Ed.; InTech: Rijeka, Croatia, 2015; pp. 329–354.

6. Gould, S.J.; Raposo, G. As we wait: Coping with an imperfect nomenclature for extracellular vesicles. *J. Extracell. Vesicles* 2013, doi:org/10.3402/jev.v2i0.20389.

7. Gyorgy, B.; Szabo, T.G.; Pasztroi, M.; Pal, Z.; Misjak, P.; Aradi, B.; Laszlo, V.; Pallinger, E.; Pap, E.; Kittel, A.; et al. Membrane vesicles, current state-of-the-art: Emerging role of extracellular vesicles. *Cell. Mol. Life Sci.* 2011, 68, 2667–2688.

8. Taylor, D.D.; Gercel-Taylor, C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. *Br. J. Cancer* 2005, 92, 305–311.
9. Cocucci, E.; Meldolesi, J. Ectosomes and exosomes: Shedding the confusion between extracellular vesicles. *Trends Cell Biol.* 2015, 25, 364–372.

10. Yuana, Y.; Sturk, A.; Nieuwland, R. Extracellular vesicles in physiological and pathological conditions. *Blood Rev.* 2013, 27, 31–39.

11. Graner, M.W. Brain tumor exosomes and microvesicles: Pleiotropic effects from tiny cellular surrogates. In *Molecular Targets of CNS Tumors*; Garami, M., Ed.; InTech Open Access: Rijeka, Croatia, 2012.

12. Lin, J.; Li, J.; Huang, B.; Liu, J.; Chen, X.; Chen, X.M.; Xu, Y.M.; Huang, L.F.; Wang, X.Z. Exosomes: Novel biomarkers for clinical diagnosis. *Sci. World J.* 2015, doi:10.1155/2015/657086.

13. Zheng, X.; Chen, F.; Zhang, J.; Zhang, Q.; Lin, J. Exosome analysis: A promising biomarker system with special attention to saliva. *J. Membr. Biol.* 2014, 247, 1129–1136.

14. Santiago-Dieppa, D.R.; Steinberg, J.; Gonda, D.; Cheung, V.J.; Carter, B.S.; Chen, C.C. Extracellular vesicles as a platform for “liquid biopsy” in glioblastoma patients. *Expert Rev. Mol. Diagn.* 2014, 14, 819–825.

15. Diaz, L.A., Jr.; Bardelli, A. Liquid biopsies: Genotyping circulating tumor DNA. *J. Clin. Oncol.* 2014, 32, 579–586.

16. Pantel, K.; Alix-Panabieres, C. Real-time liquid biopsy in cancer patients: Fact or fiction? *Cancer Res.* 2013, 73, 6384–6388.

17. Camussi, G.; Deregibus, M.C.; Bruno, S.; Cantaluppi, V.; Biancone, L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. *Kidney Int.* 2010, 78, 838–848.

18. Van Niel, G.; Mallegol, J.; Bevilacqua, C.; Candalh, C.; Brugiere, S.; Tomaskovic-Crook, E.; Heath, J.K.; Cerf-Bensussan, N.; Heyman, M. Intestinal epithelial exosomes carry mhc class ii/peptides able to inform the immune system in mice. *Gut* 2003, 52, 1690–1697.

19. Chaput, N.; Thery, C. Exosomes: Immune properties and potential clinical implementations. *Semin. Immunopathol.* 2011, 33, 419–440.

20. Thery, C.; Ostrowski, M.; Segura, E. Membrane vesicles as conveyors of immune responses. *Nat. Rev. Immunol.* 2009, 9, 581–593.

21. Zhang, X.; Yuan, X.; Shi, H.; Wu, L.; Qian, H.; Xu, W. Exosomes in cancer: Small particle, big player. *J. Hematol. Oncol.* 2015, doi:10.1093/jnci/dju170.

22. Miller, I.V.; Grunewald, T.G. Tumour-derived exosomes: Tiny envelopes for big stories. *Biol. Cell* 2015, 107, 287–305.

23. Lasser, C. Exosomes in diagnostic and therapeutic applications: Biomarker, vaccine and RNA interference delivery vehicle. *Expert Opin. Biol. Ther.* 2015, 15, 103–117.

24. Redzic, J.S.; Ung, T.H.; Graner, M.W. Glioblastoma extracellular vesicles: Reservoirs of potential biomarkers. *Pharmacogen. Personal. Med.* 2014, 7, 65–77.

25. Whiteside, T.L. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. *Semin. Cancer Biol.* 2006, 16, 3–15.

26. Hellwinkel, J.E.; Redzic, J.S.; Harland, T.A.; Gunaydin, D.; Anchordoquy, T.J.; Graner, M.W. Glioma-derived extracellular vesicles selectively suppress immune responses. *Neuro Oncol.* 2015, 8, doi:10.1093/neuonc/nov170.

27. Steinman, R.M. Decisions about dendritic cells: Past, present, and future. *Annu. Rev. Immunol.* 2012, doi:10.1146/annurev-immunol-100311-102839.
28. Vremec, D.; Shortman, K. What’s in a name? Some early and current issues in dendritic cell nomenclature. *Front. Immunol.* 2015, doi:10.3389/fimmu.2015.00267.

29. Grakoui, A.; Bromley, S.K.; Sumen, C.; Davis, M.M.; Shaw, A.S.; Allen, P.M.; Dustin, M.L. Pillars article: The immunological synapse: A molecular machine controlling T cell activation. *Science.* 1999, 285: 221–227. *J. Immunol.* 2015, 194, 4066–4072.

30. Anguille, S.; Smits, E.L.; Lion, E.; van Tendeloo, V.F.; Berneman, Z.N. Clinical use of dendritic cells for cancer therapy. *Lancet Oncol.* 2014, 15, e257–e267.

31. Carballido, E.; Fishman, M. Sipuleucel-T: Prototype for development of anti-tumor vaccines. *Curr. Oncol. Rep.* 2011, 13, 112–119.

32. Eyrich, M.; Schreiber, S.C.; Rachor, J.; Krauss, J.; Pauwels, F.; Hain, J.; Wolfl, M.; Lutz, M.B.; de Vleeschouwer, S.; Schlegel, P.G.; et al. Development and validation of a fully gmp-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. *Cytotherapy* 2014, 16, 946–964.

33. Benencia, F.; Sprague, L.; McGinty, J.; Pate, M.; Muccioli, M. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. *J. Biomed. Biotechnol.* 2012, doi:10.1155/2012/425476.

34. Kurosaki, M.; Horiguchi, S.; Yamasaki, K.; Uchida, Y.; Motohashi, S.; Nakayama, T.; Sugimoto, A.; Okamoto, Y. Migration and immunological reaction after the administration of alphagalcer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. *Cancer Immunol. Immunother.* 2011, 60, 207–215.

35. Lesterhuis, W.J.; de Vries, I.J.; Schreibelt, G.; Lambeck, A.J.; Aarntzen, E.H.; Jacobs, J.F.; Scharenborg, N.M.; van de Rakt, M.W.; de Boer, A.J.; Croockewit, S.; et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific t cells in advanced melanoma patients. *Clin. Cancer Res.* 2011, 17, 5725–5735.

36. Wu, A.A.; Drake, V.; Huang, H.S.; Chiu, S.; Zheng, L. Reprogramming the tumor microenvironment: Tumor-induced immunosuppressive factors paralyze t cells. *Oncoimmunology* 2015, 4, e1016700.

37. Katoh, H.; Watanabe, M. Myeloid-derived suppressor cells and therapeutic strategies in cancer. *Mediat. Inflamm.* 2015, doi:10.1155/2015/159269.

38. Mao, Y.; Poschke, I.; Kiessling, R. Tumour-induced immune suppression: Role of inflammatory mediators released by myelomonocytic cells. *J. Intern. Med.* 2014, 276, 154–170.

39. Whiteside, T.L.; Schuler, P.; Schilling, B. Induced and natural regulatory t cells in human cancer. *Expert Opin. Biol. Ther.* 2012, 12, 1383–1397.

40. Diener, K.R.; Need, E.F.; Buchanan, G.; Hayball, J.D. Tgf-beta signalling and immunity in prostate tumourigenesis. *Expert Opin. Ther. Targets* 2010, 14, 179–192.

41. Waziri, A. Glioblastoma-derived mechanisms of systemic immunosuppression. *Neurosurg. Clin. N. Am.* 2010, 21, 31–42.

42. Qin, F.X. Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. *Cell Mol. Immunol.* 2009, 6, 3–13.

43. Vega, E.A.; Graner, M.W.; Sampson, J.H. Combating immunosuppression in glioma. *Future Oncol.* 2008, 4, 433–442.
44. Whiteside, T.L. Immune modulation of T-cell and NK (natural killer) cell activities by texs (tumour-derived exosomes). *Biochem. Soc. Trans.* 2013, 41, 245–251.
45. Cereghetti, D.M.; Lee, P.P. Tumor-derived exosomes contain micrornas with immunological function: Implications for a novel immunosuppression mechanism. *Microrna* 2014, 2, 194–204.
46. Raposo, G.; Nijman, H.W.; Stoorvogel, W.; Liejendekker, R.; Harding, C.V.; Melief, C.J.; Geuze, H.J. B lymphocytes secrete antigen-presenting vesicles. *J. Exp. Med.* 1996, 183, 1161–1172.
47. Zitvogel, L.; Regnault, A.; Lozier, A.; Wolfers, J.; Flament, C.; Tenza, D.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. *Nat. Med.* 1998, 4, 594–600.
48. Thery, C.; Regnault, A.; Garin, J.; Wolfers, J.; Zitvogel, L.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. *J. Cell Biol.* 1999, 147, 599–610.
49. Tamura, Y.; Torigoe, T.; Kukita, K.; Saito, K.; Okuya, K.; Kutomi, G.; Hirata, K.; Sato, N. Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity. *Immunotherapy* 2012, 4, 841–852.
50. Gallucci, S.; Matzinger, P. Danger signals: Sos to the immune system. *Curr. Opin. Immunol.* 2001, 13, 114–119.
51. Seigneuric, R.; Mjahed, H.; Gobbo, J.; Joly, A.L.; Berthenet, K.; Shirley, S.; Garrido, C. Heat shock proteins as danger signals for cancer detection. *Front. Oncol.* 2011, doi:10.3389/fonc.2011.00037.
52. Vincent-Schneider, H.; Stumptner-Cuvelette, P.; Lankar, D.; Pain, S.; Raposo, G.; Benaroch, P.; Bonnerot, C. Exosomes bearing hla-dr1 molecules need dendritic cells to efficiently stimulate specific t cells. *Int. Immunol.* 2002, 14, 713–722.
53. Denzer, K.; van Eijk, M.; Kleijmeer, M.J.; Jakobson, E.; de Groot, C.; Geuze, H.J. Follicular dendritic cells carry mhc class II-expressing microvesicles at their surface. *J. Immunol.* 2000, 165, 1259–1265.
54. Thery, C.; Dublan, L.; Segura, E.; Veron, P.; Lantz, O.; Amigorena, S. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. *Nat. Immunol.* 2002, 3, 1156–1162.
55. Andre, F.; Chaput, N.; Schartz, N.E.; Flament, C.; Aubert, N.; Bernard, J.; Lemonnier, F.; Raposo, G.; Escudier, B.; Hs, D.H.; et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional mhc class I/peptide complexes to dendritic cells. *J. Immunol.* 2004, 172, 2126–2136.
56. Utsugi-Kobukai, S.; Fujimaki, H.; Hotta, C.; Nakazawa, M.; Minami, M. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. *Immunol. Lett.* 2003, 89, 125–131.
57. Sprent, J. Direct stimulation of naive t cells by antigen-presenting cell vesicles. *Blood Cells Mol. Dis.* 2005, 35, 17–20.
58. Kovar, M.; Boyman, O.; Shen, X.; Hwang, I.; Kohler, R.; Sprent, J. Direct stimulation of T cells by membrane vesicles from antigen-presenting cells. *Proc. Natl. Acad. Sci. USA* 2006, 103, 11671–11676.
59. Amigorena, S. Anti-tumour immunotherapy using dendritic-cell-derived exosomes. *Res. Immunol.* 1998, 149, 661–662.
60. Zitvogel, L.; Fernandez, N.; Lozier, A.; Wolfers, J.; Regnault, A.; Raposo, G.; Amigorena, S. Dendritic cells or their exosomes are effective biotherapies of cancer. Eur. J. Cancer 1999, 35, S36–S38.

61. Quah, B.; O’Neill, H.C. Review: The application of dendritic cell-derived exosomes in tumour immunotherapy. Cancer Biother. Radiopharmcol. 2000, 15, 185–194.

62. Chaput, N.; Schartz, N.E.; Andre, F.; Zitvogel, L. Exosomes for immunotherapy of cancer. Adv. Exp. Med. Biol. 2003, 532, 215–221.

63. Andre, F.; Escudier, B.; Angevin, E.; Tursz, T.; Zitvogel, L. Exosomes for cancer immunotherapy. Ann. Oncol. 2004, 15, iv141–iv144.

64. Lamparski, H.G.; Metha-Damani, A.; Yao, J.Y.; Patel, S.; Hsu, D.H.; Ruegg, C.; le Pecq, J.B. Production and characterization of clinical grade exosomes derived from dendritic cells. J. Immunol. Methods 2002, 270, 211–226.

65. Morse, M.A.; Garst, J.; Osada, T.; Khan, S.; Hobeika, A.; Clay, T.M.; Valente, N.; Shreeniwas, R.; Sutton, M.A.; Delcayre, A.; et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 2005, doi:10.1186/1479-5876-3-9.

66. Escudier, B.; Dorval, T.; Chaput, N.; Andre, F.; Caby, M.P.; Novault, S.; Flament, C.; Leboulaire, C.; Borg, C.; Amigorena, S.; et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of the first phase I clinical trial. J. Transl. Med. 2005, doi:10.1186/1479-5876-3-10.

67. Viaud, S.; Terme, M.; Flament, C.; Taieb, J.; Andre, F.; Novault, S.; Escudier, B.; Robert, C.; Caillat-Zucman, S.; Tursz, T.; et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: A role for NKG2D ligands and IL-15alpha. PLoS ONE 2009, 4, e4942.

68. Viaud, S.; Thery, C.; Ploix, S.; Tursz, T.; Lapiere, V.; Lantz, O.; Zitvogel, L.; Chaput, N. Dendritic cell-derived exosomes for cancer immunotherapy: What’s next? Cancer Res. 2010, 70, 1281–1285.

69. Narita, M.; Kanda, T.; Abe, T.; Uchiyama, T.; Iwafuchi, M.; Zheng, Z.; Liu, A.; Kaifu, T.; Kosugi, S.; Minagawa, M.; et al. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine. Int. J. Oncol. 2015, 46, 1699–1709.

70. Pitt, J.M.; Charrier, M.; Viaud, S.; Andre, F.; Besse, B.; Chaput, N.; Zitvogel, L. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J. Immunol. 2014, 193, 1006–1011.

71. Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 2015, 27, 450–461.

72. Naslund, T.I.; Gehrmann, U.; Qazi, K.R.; Karlsson, M.C.; Gabrielsson, S. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J. Immunol. 2013, 190, 2712–2719.

73. Gehrmann, U.; Hiltbrunner, S.; Georgoudaki, A.M.; Karlsson, M.C.; Naslund, T.I.; Gabrielsson, S. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with alpha-galactosylceramide on exosomes. Cancer Res. 2013, 73, 3865–3876.

74. Srivatsan, S.; Patel, J.M.; Bozeman, E.N.; Imasuen, I.E.; He, S.; Daniels, D.; Selvaraj, P. Allogeneic tumor cell vaccines: The promise and limitations in clinical trials. Hum. Vaccines Immunother. 2014, 10, 52–63.
75. Guan, S.; Li, Q.; Liu, P.; Xuan, X.; Du, Y. Umbilical cord blood-derived dendritic cells loaded with BGC823 tumor antigens and DC-derived exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumor immunity in vitro and in vivo. Cent. Eur. J. Immunol. 2014, 39, 142–151.

76. Bu, N.; Wu, H.; Zhang, G.; Ma, X.; Zhao, P.; Zhai, N.; Xiang, L.; Cao, H.; Yang, X.; Liu, J. Exosome from chaperone-rich cell lysates-loaded dendritic cells produced by celline 1000 culture system exhibits potent immune activity. Biochem. Biophys. Res. Commun. 2015, 456, 513–518.

77. Graner, M.; Raymond, A.; Akporiaye, E.; Katsanis, E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol. Immunother. 2000, 49, 476–484.

78. Graner, M.W.; Zeng, Y.; Feng, H.; Katsanis, E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol. Immunother. 2003, 52, 226–234.

79. Graner, M.W.; Romanoski, A.; Katsanis, E. The “peptidome” of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. Int. J. Hyperther. 2013, 29, 380–389.

80. Epple, L.M.; Bemis, L.T.; Cavanaugh, R.P.; Skope, A.; Mayer-Sonnenfeld, T.; Frank, C.; Olver, C.S.; Lencioni, A.M.; Dusto, N.L.; Tal, A.; et al. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Int. J. Hyperthermia 2013, 29, 390–398.

81. Mayer-Sonnenfeld, T.; Har-Noy, M.; Lillehei, K.O.; Graner, M.W. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for crcl’s unique structure: Crcl vaccine proteome leads to unique structure. Int. J. Hyperthermia 2013, 29, 520–527.

82. Bu, N.; Wu, H.; Zhang, G.; Zhan, S.; Zhang, R.; Sun, H.; Du, Y.; Yao, L.; Wang, H. Exosomes from dendritic cells loaded with chaperone-rich cell lysates elicit a potent t cell immune response against intracranial glioma in mice. J. Mol. Neurosci. 2015, 56, 631–643.

83. Romagnoli, G.G.; Zelante, B.B.; Toniolo, P.A.; Migliori, I.K.; Barbuto, J.A. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. Front. Immunol. 2014, doi:10.3389/fimmu.2014.00692.

84. Wolfers, J.; Lozier, A.; Raposo, G.; Regnault, A.; Thery, C.; Masurier, C.; Flamant, C.; Pouzieux, S.; Faure, F.; Tursz, T.; et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for ctl cross-priming. Nat. Med. 2001, 7, 297–303.

85. Altieri, S.L.; Khan, A.N.; Tomasi, T.B. Exosomes from plasmacytoma cells as a tumor vaccine. J. Immunother. 2004, 27, 282–288.

86. Andre, F.; Scharz, N.E.; Chaput, N.; Flamant, C.; Raposo, G.; Amigorena, S.; Angevin, E.; Zitvogel, L. Tumor-derived exosomes: A new source of tumor rejection antigens. Vaccine 2002, 20, A28–A31.

87. Lee, E.Y.; Park, K.S.; Yoon, Y.J.; Lee, J.; Moon, H.G.; Jang, S.C.; Choi, K.H.; Kim, Y.K.; Gho, Y.S. Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis. PLoS ONE 2012, 7, e33330.

88. Bu, N.; Li, Q.L.; Feng, Q.; Sun, B.Z. Immune protection effect of exosomes against attack of L1210 tumor cells. Leuk. Lymphoma 2006, 47, 913–918.
89. Graner, M.W.; Cumming, R.I.; Bigner, D.D. The heat shock response and chaperones/heat shock proteins in brain tumors: Surface expression, release, and possible immune consequences. J. Neurosci. 2007, 27, 11214–11227.

90. Graner, M.W.; Alzate, O.; Dechkovskaia, A.M.; Keene, J.D.; Sampson, J.H.; Mitchell, D.A.; Bigner, D.D. Proteomic and immunologic analyses of brain tumor exomes. FASEB J. 2009, 23, 1541–1557.

91. Mulcahy, L.A.; Pink, R.C.; Carter, D.R. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles 2014, 3, doi:10.3402/jev.v3.24641.

92. Hao, S.; Bai, O.; Yuan, J.; Qureshi, M.; Xiang, J. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol. Immunol. 2006, 3, 205–211.

93. Gu, X.; Erb, U.; Buchler, M.W.; Zoller, M. Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int. J. Cancer 2015, 136, E74–E84.

94. Dai, S.; Wan, T.; Wang, B.; Zhou, X.; Xi, F.; Chen, T.; Wu, Y.; Cao, X. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed cea-positive tumor cells. Clin. Cancer Res. 2005, 11, 7554–7563.

95. Cho, J.A.; Lee, Y.S.; Kim, S.H.; Ko, J.K.; Kim, C.W. Mhc independent anti-tumor immune responses induced by hsp70-enriched exosomes generate tumor regression in murine models. Cancer Lett. 2009, 275, 256–265.

96. Xie, Y.; Bai, O.; Zhang, H.; Yuan, J.; Zong, S.; Chibbar, R.; Slattery, K.; Qureshi, M.; Wei, Y.; Deng, Y.; et al. Membrane-bound hsp70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic hsp70. J. Cell. Mol. Med. 2010, 14, 2655–2666.

97. Chen, T.; Guo, J.; Yang, M.; Zhu, X.; Cao, X. Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine. J. Immunol. 2011, 186, 2219–2228.

98. Yang, Y.; Xiu, F.; Cai, Z.; Wang, J.; Wang, Q.; Fu, Y.; Cao, X. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J. Cancer Res. Clin. Oncol. 2007, 133, 389–399.

99. Xie, Y.; Bai, O.; Zhang, H.; Li, W.; Xiang, J. Tumor necrosis factor gene-engineered j558 tumor cell-released exosomes stimulate tumor antigen p1a-specific CD8+ CTL responses and antitumor immunity. Cancer Biother. Radiopharm. 2010, 25, 21–28.

100. Lee, Y.S.; Kim, S.H.; Cho, J.A.; Kim, C.W. Introduction of the ciita gene into tumor cells produces exosomes with enhanced anti-tumor effects. Exp. Mol. Med. 2011, 43, 281–290.

101. Rountree, R.B.; Mandl, S.J.; Nachtwey, J.M.; Dalpozzo, K.; Do, L.; Lombardo, J.R.; Schoonmaker, P.L.; Brinkmann, K.; Dirmeier, U.; Laus, R.; et al. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011, 71, 5235–5244.

102. Zeelenberg, I.S.; van Maren, W.W.; Boissonnas, A.; van Hout-Kuijer, M.A.; den Brok, M.H.; Wagenaars, J.A.; van der Schaaf, A.; Jansen, E.J.; Amigorena, S.; Thery, C.; et al. Antigen localization controls T cell-mediated tumor immunity. J. Immunol. 2011, 187, 1281–1288.
103. Sedlik, C.; Vigneron, J.; Torrieri-Dramard, L.; Pitoiset, F.; Denizeau, J.; Chesneau, C.; de la Rochere, P.; Lantz, O.; Thery, C.; Bellier, B. Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated forms. *J. Extracell. Vesicles* 2014, doi:10.3402/jev.v3.24646.

104. Hartman, Z.C.; Wei, J.; Glass, O.K.; Guo, H.; Lei, G.; Yang, X.Y.; Osada, T.; Hobeika, A.; Delcayre, A.; le Pecq, J.B.; et al. Increasing vaccine potency through exosome antigen targeting. *Vaccine* 2011, 29, 9361–9367.

105. Zeelenberg, I.S.; Ostrowski, M.; Krumeich, S.; Bobrie, A.; Jancic, C.; Boissonnas, A.; Delcayre, A.; le Pecq, J.B.; Combadiere, B.; Amigorena, S.; et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. *Cancer Res.* 2008, 68, 1228–1235.

106. Xiu, F.; Cai, Z.; Yang, Y.; Wang, X.; Wang, J.; Cao, X. Surface anchorage of superantigen sea promotes induction of specific antitumor immune response by tumor-derived exosomes. *J. Mol. Med.* 2007, 85, 511–521.

107. Dai, S.; Wei, D.; Wu, Z.; Zhou, X.; Wei, X.; Huang, H.; Li, G. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. *Mol. Ther.* 2008, 16, 782–790.

108. Graner, M.W.; Bigner, D.D. Chaperone proteins and brain tumors: Potential targets and possible therapeutics. *Neuro Oncol.* 2005, 7, 260–278.

109. Graner, M.W.; Bigner, D.D. Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology. *Expert Rev. Anticancer Ther.* 2006, 6, 679–695.

110. Toraya-Brown, S.; Fiering, S. Local tumour hyperthermia as immunotherapy for metastatic cancer. *Int. J. Hyperth.* 2014, 30, 531–539.

111. Jego, G.; Hazoume, A.; Seigneuric, R.; Garrido, C. Targeting heat shock proteins in cancer. *Cancer Lett.* 2013, 332, 275–285.

112. Lv, L.H.; Wan, Y.L.; Lin, Y.; Zhang, W.; Yang, M.; Li, G.L.; Lin, H.M.; Shang, C.Z.; Chen, Y.J.; Min, J. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. *J. Biol. Chem.* 2012, 287, 15874–15885.

113. Xiao, W.; Dong, W.; Zhang, C.; Saren, G.; Geng, P.; Zhao, H.; Li, Q.; Zhu, J.; Li, G.; Zhang, S.; et al. Effects of the epigenetic drug ms-275 on the release and function of exosome-related immune molecules in hepatocellular carcinoma cells. *Eur. J. Med. Res.* 2013, 18, doi:10.1186/2047-783X-18-61.

114. Mincheva-Nilsson, L.; Baranov, V. Cancer exosomes and NKG2D receptor-ligand interactions: Impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance. *Semin. Cancer Biol.* 2014, 24, 28–30.

115. Parmiani, G.; Rodolfo, M.; Melani, C. Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal. *Hum. Gene Ther.* 2000, 11, 1269–1275.

116. Zhang, J.; Zhang, Y.; Luo, C.; Xia, Y.; Chen, H.; Wu, X. Glycosyl-phosphatidylinositol-anchored interleukin-2 expressed on tumor-derived exosomes induces antitumor immune response in vitro. *Tumori* 2010, 96, 452–459.

117. Napoletano, C.; Rughetti, A.; Landi, R.; Pinto, D.; Bellati, F.; Rahimi, H.; Spinelli, G.P.; Pauselli, S.; Sale, P.; Dolo, V.; et al. Immunogenicity of allo-vesicle carrying ErbB2 tumor antigen
for dendritic cell-based anti-tumor immunotherapy. *Int. J. Immunopathol. Pharmacol.* 2009, 22, 647–658.

118. Delcayre, A.; Estelles, A.; Sperinde, J.; Roulon, T.; Paz, P.; Aguilar, B.; Villanueva, J.; Khine, S.; le Pecq, J.B. Exosome display technology: Applications to the development of new diagnostics and therapeutics. *Blood Cells Mol. Dis.* 2005, 35, 158–168.

119. Adams, M.; Navabi, H.; Croston, D.; Coleman, S.; Tabi, Z.; Clayton, A.; Jasani, B.; Mason, M.D. The rationale for combined chemo/immunotherapy using a toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. *Vaccine* 2005, 23, 2374–2378.

120. Andre, F.; Schartz, N.E.; Movassagh, M.; Flament, C.; Pautier, P.; Morice, P.; Pomel, C.; Lhomme, C.; Escudier, B.; le Chevalier, T.; et al. Malignant effusions and immunogenic tumour-derived exosomes. *Lancet* 2002, 360, 295–305.

121. Navabi, H.; Croston, D.; Hobot, J.; Clayton, A.; Zitvogel, L.; Jasani, B.; Bailey-Wood, R.; Wilson, K.; Tabi, Z.; Mason, M.D.; et al. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. *Blood Cells Mol. Dis.* 2005, 35, 149–152.

122. Liu, Y.; Gu, Y.; Cao, X. The exosomes in tumor immunity. *Oncoimmunology* 2015, 4, e1027472.

123. Robbins, P.D.; Morelli, A.E. Regulation of immune responses by extracellular vesicles. *Nat. Rev. Immunol.* 2014, 14, 195–208.

124. Zhang, H.G.; Zhuang, X.; Sun, D.; Liu, Y.; Xiang, X.; Grizzle, W.E. Exosomes and immune surveillance of neoplastic lesions: A review. *Biotech. Histochem.* 2012, 87, 161–168.

125. Valenti, R.; Huber, V.; Iero, M.; Filipazzi, P.; Parmiani, G.; Rivoltini, L. Tumor-released microvesicles as vehicles of immunosuppression. *Cancer Res.* 2007, 67, 2912–2915.

126. Andreola, G.; Rivoltini, L.; Castelli, C.; Huber, V.; Perego, P.; Deho, P.; Squarcina, P.; Accornero, P.; Lozupone, F.; Lugini, L.; et al. Induction of lymphocyte apoptosis by tumor cell secretion of fasl-bearing microvesicles. *J. Exp. Med.* 2002, 195, 1303–1316.

127. Kim, J.W.; Wieckowski, E.; Taylor, D.D.; Reichert, T.E.; Watkins, S.; Whiteside, T.L. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. *Clin. Cancer Res.* 2005, 11, 1010–1020.

128. Abusamra, A.J.; Zhong, Z.; Zheng, X.; Li, M.; Ichim, T.E.; Chin, J.L.; Min, W.P. Tumor exosomes expressing fas ligand mediate CD8+ T-cell apoptosis. *Blood Cells Mol. Dis.* 2005, 35, 169–173.

129. Ichim, T.E.; Zhong, Z.; Kaushal, S.; Zheng, X.; Ren, X.; Hao, X.; Joyce, J.A.; Hanley, H.H.; Riordan, N.H.; Koropatnick, J.; et al. Exosomes as a tumor immune escape mechanism: Possible therapeutic implications. *J. Transl. Med.* 2008, doi:10.1186/1479-5876-6-37.

130. Clayton, A.; Al-Taei, S.; Webber, J.; Mason, M.D.; Tabi, Z. Cancer exosomes express CD39 and CD73, which suppress t cells through adenosine production. *J. Immunol.* 2011, 187, 676–683.

131. Clayton, A.; Mitchell, J.P.; Court, J.; Mason, M.D.; Tabi, Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. *Cancer Res.* 2007, 67, 7458–7466.

132. Szajnik, M.; Czystowska, M.; Szczepanski, M.J.; Mandapathil, M.; Whiteside, T.L. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). *PLoS ONE* 2010, 5, e11469.

133. Battke, C.; Ruiss, R.; Welsch, U.; Wimberger, P.; Lang, S.; Jochum, S.; Zeidler, R. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. *Cancer Immunol. Immunother.* 2011, 60, 639–648.
134. Aung, T.; Chapuy, B.; Vogel, D.; Wenzel, D.; Oppermann, M.; Lahmann, M.; Weinrage, T.; Menck, K.; Hupfeld, T.; Koch, R.; et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 15336–15341.

135. Graner, M.W.; Epple, L.M.; Dusto, N.L.; Lencioni, A.M.; Nega, M.; Herring, M.; Winston, B.; Madsen, H.; Bemis, L.T.; Anchordoquy, T.J. Circulating exosomes as new biomarkers for brain disease and injury. In *Proceedings of SPIE Vol. 8723 Sensing Technologies for Global Health, Military Medicine, and Environmental Monitoring III*; Baltimore, MD, USA, 29 Apr–1 May 2013; Southern, S.O., Ed.

136. Clayton, A.; Tabi, Z. Exosomes and the mica-NKG2D system in cancer. *Blood Cells Mol. Dis.* **2005**, *34*, 206–213.

137. Szczepanski, M.J.; Szajnik, M.; Welsh, A.; Whiteside, T.L.; Boyiadzis, M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. *Haematologica* **2011**, *96*, 1302–1309.

138. Clayton, A.; Mitchell, J.P.; Court, J.; Linnane, S.; Mason, M.D.; Tabi, Z. Human tumor-derived exosomes down-modulate NKG2D expression. *J. Immunol.* **2008**, *180*, 7249–7258.

139. Hedlund, M.; Nagaeva, O.; Kargl, D.; Baranov, V.; Mincheva-Nilsson, L. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma t and b cells. *PLoS ONE* **2011**, *6*, e16899.

140. Gastpar, R.; Gehrmann, M.; Bausero, M.A.; Asea, A.; Gross, C.; Schroeder, J.A.; Multhoff, G. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. *Cancer Res.* **2005**, *65*, 5238–5247.

141. Elsner, L.; Muppala, V.; Gehrmann, M.; Lozano, J.; Malzahn, D.; Bickeboller, H.; Brunner, E.; Zientkowska, M.; Herrmann, T.; Walter, L.; et al. The heat shock protein hsp70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. *J. Immunol.* **2007**, *179*, 5523–5533.

142. Yu, S.; Liu, C.; Su, K.; Wang, J.; Liu, Y.; Zhang, L.; Li, C.; Cong, Y.; Kimberly, R.; Grizzle, W.E.; et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. *J. Immunol.* **2007**, *178*, 6867–6875.

143. Xiang, X.; Poliakov, A.; Liu, C.; Liu, Y.; Deng, Z.B.; Wang, J.; Cheng, Z.; Shah, S.V.; Wang, G.J.; Zhang, L.; et al. Induction of myeloid-derived suppressor cells by tumor exosomes. *Int. J. Cancer* **2009**, *124*, 2621–2633.

144. Chalmin, F.; Ladoire, S.; Mignot, G.; Vincent, J.; Bruchard, M.; Remy-Martin, J.P.; Boireau, W.; Rouleau, A.; Simon, B.; Lanneau, D.; et al. Membrane-associated hsp72 from tumor-derived exosomes mediates stat3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. *J. Clin. Investig.* **2010**, *120*, 457–471.

145. Chow, A.; Zhou, W.; Liu, L.; Fong, M.Y.; Champer, J.; van Haute, D.; Chin, A.R.; Ren, X.; Gugiu, B.G.; Meng, Z.; et al. Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappab. *Sci. Rep.* **2014**, doi:10.1038/srep05750.
146. De Vrij, J.; Maas, S.L.; Kwappenberg, K.M.; Schnoor, R.; Kleijn, A.; Dekker, L.; Luider, T.M.; de Witte, L.D.; Litjens, M.; van Strien, M.E.; et al. Glioblastoma-derived extracellular vesicles modify the phenotype of monocyctic cells. *Int. J. Cancer* 2015, 137, 1630–1642.

147. Marton, A.; Vizler, C.; Kusz, E.; Temesfoi, V.; Szathmary, Z.; Nagy, K.; Szegletes, Z.; Varo, G.; Siklos, L.; Katona, R.L.; et al. Melanoma cell-derived exosomes alter macrophage and dendritic cell functions *in vitro*. *Immunol. Lett.* 2012, 148, 34–38.

148. He, M.; Qin, H.; Poon, T.C.; Sze, S.C.; Ding, X.; Co, N.N.; Ngai, S.M.; Chan, T.F.; Wong, N. Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and mRNAs. *Carcinogenesis* 2015, 36, 1008–1018.

149. Melo, S.A.; Sugimoto, H.; O’Connell, J.T.; Kato, N.; Villanueva, A.; Vidal, A.; Qiu, L.; Vitkin, E.; Perelman, L.T.; Melo, C.A.; et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. *Cancer Cell* 2014, 26, 707–721.

150. Ye, S.B.; Li, Z.L.; Luo, D.H.; Huang, B.J.; Chen, Y.S.; Zhang, X.S.; Cui, J.; Zeng, Y.X.; Li, J. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. *Oncotarget* 2014, 5, 5439–5452.

151. Yu, D.D.; Wu, Y.; Shen, H.Y.; Lv, M.M.; Chen, W.X.; Zhang, X.H.; Zhong, S.L.; Tang, J.H.; Zhao, J.H. Exosomes in development, metastasis and drug resistance of breast cancer. *Cancer Sci.* 2015, 106, 959–964.

152. Scheerlinck, J.P.; Greenwood, D.L. Virus-sized vaccine delivery systems. *Drug Discov. Today* 2008, 13, 882–887.

153. Lattanzi, L.; Federico, M. A strategy of antigen incorporation into exosomes: Comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particles. *Vaccine* 2012, 30, 7229–7237.

154. Smyth, T.J.; Redzic, J.S.; Graner, M.W.; Anchordoquy, T.J. Examination of the specificity of tumor cell-derived exosomes with tumor cells *in vitro*. *Biochim. Biophys. Acta* 2014, 1838, 2954–2965.

155. Smyth, T.; Petrova, K.; Payton, N.M.; Persaud, I.; Redzic, J.S.; Graner, M.W.; Smith-Jones, P.; Anchordoquy, T.J. Surface functionalization of exosomes using click chemistry. *Bioconjugate Chem.* 2014, 25, 1777–1784.

156. Gyorgy, B.; Hung, M.E.; Breakfield, X.O.; Leonard, J.N. Therapeutic applications of extracellular vesicles: Clinical promise and open questions. *Annu. Rev. Pharmacol. Toxicol.* 2015, 55, 439–464.

157. Gehrmann, U.; Naslund, T.I.; Hiltbrunner, S.; Larssen, P.; Gabrielsson, S. Harnessing the exosome-induced immune response for cancer immunotherapy. *Semin. Cancer Biol.* 2014, 28, 58–67.

158. Barua, S.; Mitragotri, S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects. *Nano Today* 2014, 9, 223–243.

159. Kim, S.H.; Bianco, N.; Menon, R.; Lechman, E.R.; Shufesky, W.J.; Morelli, A.E.; Robbins, P.D. Exosomes derived from genetically modified DC expressing Fasl are anti-inflammatory and immunosuppressive. *Mol. Ther.* 2006, 13, 289–300.

160. Segura, E.; Guerin, C.; Hogg, N.; Amigorena, S.; Thery, C. CD8+ dendritic cells use LFA-1 to capture MHC-peptide complexes from exosomes *in vivo*. *J. Immunol.* 2007, 179, 1489–1496.
161. Iero, M.; Valenti, R.; Huber, V.; Filipazzi, P.; Parmiani, G.; Fais, S.; Rivoltini, L. Tumour-released exosomes and their implications in cancer immunity. *Cell Death Differ.* **2008**, *15*, 80–88.

162. Bai, J.; Xie, X.; Lei, Y.; An, G.; He, L.; Chen, R. Consideration of dual characters of exosomes in the tumour immune response. *Cell Biol. Int.* **2014**, *38*, 538–545.

163. Lu, M.; Huang, B.; Hanash, S.M.; Onuchic, J.N.; Ben-Jacob, E. Modeling putative therapeutic implications of exosome exchange between tumor and immune cells. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E4165–E4174.

164. Marleau, A.M.; Chen, C.S.; Joyce, J.A.; Tullis, R.H. Exosome removal as a therapeutic adjuvant in cancer. *J. Transl. Med.* **2012**, doi:10.1186/1479-5876-10-134.

165. Podack, E.R.; Raez, L.E. Allogeneic tumor-cell-based vaccines secreting endoplasmic reticulum chaperone gp96. *Expert Opin. Biol. Ther.* **2007**, *7*, 1679–1688.

166. Ito, A.; Kondo, S.; Tada, K.; Kitano, S. Clinical development of immune checkpoint inhibitors. *BioMed Res. Int.* **2015**, doi:10.1155/2015/605478.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).